The DOI matches its Crossref record; the references it cites are not checked yet.
Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice
Open accessAbstract
Glucagon-like peptide-1 (GLP-1) receptor agonists potentiate glucose-induced insulin secretion. In addition, they have been reported to increase pancreatic beta cell mass in diabetic rodents. However, the precise mode of action of GLP-1 receptor agonists still needs to be elucidated. Here we clarify the effects of the human GLP-1 analog liraglutide on beta cell fate and function by using an inducible Cre/loxP-based pancreatic beta cell tracing system and alloxan-induced diabetic mice. Liraglutide was subcutaneously administered once daily for 30 days. The changes in beta cell mass were examined as well as glucose tolerance and insulin secretion. We found that chronic liraglutide treatment improved glucose tolerance and insulin response to oral glucose load. Thirty-day treatment with liraglutide resulted in a 2-fold higher mass of pancreatic beta cells than that in vehicle group. Liraglutide increased proliferation rate of pancreatic beta cells and prevented beta cells from apoptotic cells death. However, the relative abundance of YFP-labeled beta cells to total beta cells was no different before and after liraglutide treatment, suggesting no or little contribution of neogenesis to the increase in beta cell mass. Liraglutide reduced oxidative stress in pancreatic islet cells of alloxan-induced diabetic mice. Furthermore, the beneficial effects of liraglutide in these mice were maintained two weeks after drug withdrawal. In conclusion, chronic liraglutide treatment improves hyperglycemia by ameliorating beta cell mass and function in alloxan-induced diabetic mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, it has been shown that chronic liraglutide treatment in diabetic mice prevents loss of pancreatic beta-cell mass, increases proliferation of the beta-cells and decreases apoptosis after alloxan injection.264”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [264]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 44 · Cited by 70
Research works printed but not linked: 1
- K Minami, 2011, Self-replication is not the only mechanism of maintenance of pancreatic beta cell mass after birth, Diabetologia, 54, S26
Metadata
- Authors
- Tamura, K., Minami, K., Kudo, M., Iemoto, K., Takahashi, H., & Seino, S.
- Affiliations
- Kobe University (JP)
- Corresponding author
- Minami, Kohtaro
- Seino, Susumu
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-05-04
- Volume
- 10
- Issue
- 5
- Pages
- e0126003
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4418765
- OpenAlex
- W2161155577
- Cited by
- 70
- References
- 44
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 10 · 2019: 3 · 2018: 10 · 2017: 10 · 2015: 2
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Kobe University Repository Kernel (Kobe University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Novo Nordisk
- Novo Nordisk Pharma
- Japan Society for the Promotion of Science (24229007, 25461351)
- Japan Science and Technology Agency (CREST)
- Core Research for Evolutional Science and Technology
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- liraglutide, GLP-1 receptor agonists, beta-cell mass, beta-cell proliferation, beta-cell apoptosis, alloxan-induced diabetes, glucose tolerance, insulin secretion, oxidative stress, neogenesis, drug withdrawal
- MeSH terms
- Liraglutide, Alloxan, Animals, Blood Glucose, Diabetes Mellitus, Experimental, Energy Metabolism, Glucose Tolerance Test, Hyperglycemia, Hypoglycemic Agents, Insulin, Mice, Transgenic, Apoptosis, Oxidative Stress, Cell Size, Cell Proliferation, Insulin-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice. https://app.cochat.ai/papers/10.1371/journal.pone.0126003
- The paper
- Tamura, K., Minami, K., Kudo, M., Iemoto, K., Takahashi, H., & Seino, S. (2015). Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0126003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.